The Latest Breaking News from Merck

Merck's COVID-19 Pill works Against Omicron, Lab Studies Show

Merck & Co Inc (NYSE: MRK) and its partner Ridgeback Biotherapeutics said six lab studies showed their investigational oral COVID-19 drug molnupiravir was 

Benzinga · Jan 28, 2022

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jan 28, 2022

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19, 

Benzinga · Jan 24, 2022

Dozens of firms to make cheap version of Merck COVID pill for poorer nations

Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck Co's COVID-19 pill, under a landmark U.N.-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic.

Reuters · Jan 20, 2022

France to ease restrictions; Austrian parliament approves mandatory vaccination – as it happened

French PM says from February work from home guidance will be changed and nightclubs reopen; Austria will have Europe’s first universal jabs mandate

The Guardian - UK · Jan 20, 2022

Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial

Merck & Co Inc (NYSE: MRK) has 

Benzinga · Jan 19, 2022